With the rise of immunotherapy, immune checkpoint inhibitors (PD-1, CART, CTLA4, PD-L1 and PD-Ls) have made progress in the treatment and prognosis of HCC patients [8,9]. The gene discussed is CD274; the disease is hepatocellular carcinoma.